EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Receives Average Rating of Buy from Analysts

Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT – Get Free Report) have received a consensus recommendation of “Buy” from the six analysts that are presently covering the stock, MarketBeat reports. Six investment analysts have rated the stock with a buy rating. The average twelve-month target price among brokerages that have issued a report on the stock […]

Related Keywords

,Insider Transactions At Eyepoint Pharmaceuticals ,Schonfeld Strategic Advisors ,Toth Financial Advisory Corp ,News Ratings For Eyepoint Pharmaceuticals Daily ,Barclays Plc ,Nasdaq ,Eyepoint Pharmaceuticals ,Cantor Fitzgerald ,Lazard Asset Management ,Eyepoint Pharmaceuticals Inc ,Tower Research Capital ,Analyst Recommendations For Eyepoint Pharmaceuticals ,Hedge Funds Weigh In On Eyepoint Pharmaceuticals ,Eyepoint Pharmaceuticals Company Profile ,Eyepoint Pharmaceuticals Stock Performance ,Securities Exchange Commission ,Get Free Report ,One Financial ,Point Pharmaceuticals ,Cormorant Asset Management ,Exchange Commission ,Director Ye Liu ,Financial Advisory Corp ,Strategic Advisors ,Research Capital ,Get Free ,Eyepoint Pharmaceuticals Daily ,Nasdaq Eypt ,Eypt ,Medical ,Ratings ,Consensus ,